Oncotarget

Research Papers:

The ERβ4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERβ variants ERβ2 and ERβ5 increase aggressiveness of TNBC by regulation of hypoxic signaling

Michelle Faria _, Samaneh Karami, Sergio Granados-Principal, Prasenjit Dey, Akanksha Verma, Dong S. Choi, Olivier Elemento, Tasneem Bawa-Khalfe, Jenny C. Chang, Anders M. Strom and Jan-Åke Gustafsson

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:12201-12211. https://doi.org/10.18632/oncotarget.24134

Metrics: PDF 667 views  |   HTML 1940 views  |   ?  


Abstract

Michelle Faria1, Samaneh Karami1, Sergio Granados-Principal2, Prasenjit Dey3,4, Akanksha Verma5, Dong S. Choi6, Olivier Elemento5, Tasneem Bawa-Khalfe1, Jenny C. Chang6, Anders M. Strom1 and Jan-Åke Gustafsson1,7

1University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science & Engineering Research Center, Houston, Texas, USA

2Department of Medical Oncology, Hospital of Jaen, Jaen, Spain

3Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

4Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

5Institute for Computational Biomedicine, Department of Physiology and Biophysics Weill Cornell Medicine, New York, NY, USA

6Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas, USA

7Department of BioSciences and Nutrition, Karolinska Institutet, Huddinge, Sweden

Correspondence to:

Anders M. Strom, email: amstrom@uh.edu

Keywords: slug; twist1; SOX2; CD133; c-Myc

Received: July 22, 2017     Accepted: November 05, 2017     Published: January 10, 2018

ABSTRACT

Triple negative breast cancer (TNBC) still remains a challenge to treat in the clinic due to a lack of good targets for treatment. Although TNBC lacks expression of ERα, the expression of ERβ and its variants are detected quite frequently in this cancer type and can represent an avenue for treatment. We show that two of the variants of ERβ, namely ERβ2 and ERβ5, control aggressiveness of TNBC by regulating hypoxic signaling through stabilization of HIF-1α. RNA-seq of patient derived xenografts (PDX) from TNBC shows expression of ERβ2, ERβ4 and ERβ5 variants in more than half of the samples. Furthermore, expression of ERβ4 in the immortalized, normal mammary epithelial cell line MCF-10A that is resistant to tumorsphere formation caused transformation and development of tumorspheres. By contrast, ERβ1, ERβ2 or ERβ5 were unable to support tumorsphere formation. We have previously shown that all variants except ERβ1 stabilize HIF-1α but only ERβ4 appears to have the ability to transform normal mammary epithelial cells, pointing towards a unique property of ERβ4. We propose that ERβ variants may be good diagnostic tools and also serve as novel targets for treatment of breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24134